EBMT 2018 | Autologous transplant advances: induction and maintenance

Paul Richardson

Autologous stem cell transplantation can prove to be safer in some instances compared with allogeneic transplantation for treating hematological malignancies. Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, highlights the importance of administering lenalidomide, bortezomib and dexamethasone (RVd), to maximize efficacy and limit toxicity. Recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Share this video